Contineum Therapeutics Reports Positive Phase 1b PET Trial Results for PIPE-791 in Multiple Sclerosis and Pulmonary Fibrosis
核心洞察
Contineum Therapeutics announced positive topline data from its Phase 1b PET trial of PIPE-791, an LPA1 receptor (搜索) antagonist being developed for idiopathic pulmonary fibrosis (搜索), progressive multiple sclerosis (搜索), and chronic pain (搜索).
The trial successfully assessed the correlation between pharmacokinetics and LPA1 receptor (搜索) occupancy using PET imaging in 12 healthy volunteers and four progressive multiple sclerosis (搜索) patients.
Based on brain receptor occupancy data, the company expressed confidence in planned doses for future Phase 2 proof-of-concept trials, with researchers believing brain distribution patterns can predict lung receptor occupancy.
Contineum Therapeutics has reported positive topline data from its Phase 1b positron emission tomography (PET) trial of PIPE-791, marking a significant milestone for the clinical-stage biopharmaceutical company's lead LPA1 receptor (搜索) antagonist program. The trial successfully demonstrated the correlation between pharmacokinetics and LPA1 receptor occupancy (RO) using advanced PET imaging technology.
Trial Design and Participants
The Phase 1b, open-label, single-center trial enrolled 12 healthy volunteers and four patients with progressive multiple sclerosis (搜索) (PrMS). The study was specifically designed to assess the correlation between pharmacokinetics and LPA1 RO using PET imaging across both healthy participants and patients with neuroinflammatory conditions.
Key Findings and Clinical Implications
"Based on the distribution pattern of PIPE-791, we believe the brain is an appropriate surrogate for predicting RO in the lungs," said Daniel Lorrain, Ph.D., Chief Scientific Officer at Contineum Therapeutics. This finding has important implications for the drug's development across multiple therapeutic areas, as PIPE-791 is being developed for idiopathic pulmonary fibrosis (搜索) (IPF), progressive multiple sclerosis (搜索), and chronic pain (搜索).
The company expressed confidence in its dose selection strategy for upcoming Phase 2 trials. "We are confident in the planned doses for our future Phase 2 proof-of-concept clinical trials based upon brain RO and our completed preclinical work," Lorrain added.
PIPE-791 Development Program
PIPE-791 is an oral small molecule LPA1 receptor (搜索) antagonist that represents a key component of Contineum's pipeline targeting neuroinflammatory and immunological (NI&I) indications with significant unmet medical needs. The drug candidate is currently in clinical development for three distinct therapeutic areas: idiopathic pulmonary fibrosis (搜索), progressive multiple sclerosis (搜索), and chronic pain (搜索).
Company Pipeline and Strategic Focus
Contineum Therapeutics is advancing multiple internally-developed programs with several drug candidates now in clinical trials. Beyond PIPE-791, the company is also developing PIPE-307, a selective inhibitor of the M1 receptor (搜索) in clinical development for relapsing-remitting multiple sclerosis (搜索) and major depressive disorder (搜索). The company has established a global license and development agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, for PIPE-307 development.
Next Steps and Future Development
The positive PET trial results are expected to inform dose selection for the company's planned Phase 2 proof-of-concept clinical trials. The data suggesting that brain receptor occupancy can serve as a surrogate for lung receptor occupancy could streamline future clinical development by providing a more accessible biomarker for monitoring drug activity across different organ systems.
The trial information is available at clinicaltrials.gov under identifier NCT06683612, reflecting the company's commitment to transparency in clinical research.